Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Recent News

Carfilzomib-Based Therapy for High-Risk Smoldering Multiple Myeloma
Is Hypercalcemia Linked to Poor Survival in Newly Diagnosed Multiple Myeloma?
Investigational Immunotherapy Focus of Phase I Trial in Resistant Myeloma
ASH 2020: Intravenous and Subcutaneous Teclistamab for Resistant Multiple Myeloma
Selinexor Approved by FDA for Refractory or Relapsed Multiple Myeloma
ASH 2020: Ciltacabtagene Autoleucel Under Study in Resistant Myeloma
Daratumumab Plus Pomalidomide and Low-Dose Dexamethasone in Myeloma: Immune-Mediated Cytotoxicity
ASH 2020: Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone in Resistant Myeloma
Are Carfilzomib-Based Regimens Safe and Effective for Frail Patients With Myeloma?
ASH 2020: Novel Immunotherapy Plus Chemotherapy in Resistant Multiple Myeloma
ASH 2020: BCMA-Targeted Antibody-Drug Conjugate in Resistant Multiple Myeloma
Myeloma and COVID-19: Dana-Farber and Quest Diagnostics Collaborate on IMPACT Study
Trends in Myeloma by Age: Treatment and Outcome Disparities Explored
ARROW Trial: Once- or Twice-Weekly Carfilzomib Plus Dexamethasone in Myeloma
Ixazomib Plus Lenalidomide/Dexamethasone for Transplant-Ineligible Patients With Myeloma
ASTRO 2020: Low-Dose Radiotherapy for Painful Osseous Lesions in Patients With Myeloma
ASTRO 2020: U.S. Trends in Use of Palliative Radiotherapy for Myeloma
Novel Peptide-Drug Conjugate Plus Dexamethasone Under Study in Resistant Myeloma
Pegfilgrastim Versus Filgrastim for Heavily Pretreated Patients With Multiple Myeloma
Adding Daratumumab to Carfilzomib-Based Therapy in Resistant Myeloma: CANDOR Trial
Post-Hoc Analysis of Belantamab Mafodotin in Resistant Myeloma From DREAMM-2
Salvage Therapy Under Study for Resistant Myeloma With Extramedullary Disease
SOHO 2020: Cross-Study Comparison of Carfilzomib, Dexamethasone, and Daratumumab Dosing Regimens in Myeloma
Triplet Regimens Compared in Newly Diagnosed Multiple Myeloma: ENDURANCE Trial
Older Adults With Myeloma: Second Primary Malignancy and Lenalidomide Therapy
Do Diagnostic Pathways Determine Multiple Myeloma Severity?
SOHO 2020: Fixed-Volume Isatuximab in Resistant Multiple Myeloma
Chromosome 1q Abnormalities in Patients With Myeloma: Predictive of Inferior Outcomes?
Transplant-Ineligible Myeloma: Comparing Regimens With and Without Daratumumab
Multiple Myeloma and COVID-19: Treatment Lessons Learned
FDA Brief: Priority Review for Melphalan Flufenamide Combination in Myeloma
Invasive Fungal Infections and Early Mortality in Patients With Multiple Myeloma
Bortezomib-Based Regimens Compared for Myeloma-Related Acute Kidney Injury
Daratumumab Combination Approved by FDA in Resistant Multiple Myeloma
Transplantation for Myeloma: Outcomes for Patients With Clonal Hematopoiesis
Differential Risks for Multiple Myeloma in New York City Neighborhoods
COVID-19 and Myeloma: Continuity of Care in Italian Tertiary Hospital
DREAMM-4 Trial Update of Belantamab Mafodotin in Myeloma
FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
Ongoing Phase III Trial Compares Venetoclax With Standard Therapy for Resistant Myeloma
Vaccinating Against Pneumonia in Patients With Myeloma
AACR COVID-19: Older Patients With Multiple Myeloma at Risk
Subgroup Analysis of Isatuximab-Based Therapy for Resistant Myeloma
AACR COVID-19: Psychosocial Distress Among Patients With Active Myeloma
FDA Advisory Panel Votes in Favor of Approving Belantamab Mafodotin in Myeloma
FDA Accepts Supplemental New Drug Application for Selinexor in Myeloma


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.